(-0.05%) 5 476.00 points
(-0.08%) 38 787 points
(-0.02%) 19 918 points
(0.30%) $80.57
(1.18%) $2.82
(0.24%) $2 334.60
(-0.17%) $29.34
(-0.21%) $968.90
(0.01%) $0.932
(-0.14%) $10.64
(0.06%) $0.788
(-1.87%) $86.80
Live Chart Being Loaded With Signals
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation...
Stats | |
---|---|
Šios dienos apimtis | 95 979 |
Vidutinė apimtis | 216 319 |
Rinkos kapitalizacija | 99.65M |
EPS | $-0.690 ( Q1 | 2024-05-15 ) |
Kita pelno data | ( $-0.750 ) 2024-08-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.850 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00900 (0.35%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-24 | Romano Kelly A | Buy | 20 900 | Stock Option (Right to Buy) |
2024-05-24 | Edelman Joseph | Buy | 20 900 | Stock Option (Right to Buy) |
2024-05-24 | Johnson James A | Buy | 20 900 | Stock Option (Right to Buy) |
2024-05-24 | Kosacz Barbara | Buy | 20 900 | Stock Option (Right to Buy) |
2024-05-24 | Panzara Michael A. | Buy | 20 900 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
98.74 |
Last 99 transactions |
Buy: 6 714 749 | Sell: 65 252 |
Tūris Koreliacija
Athira Pharma, Inc. Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
OZEM | 1 |
XERS | 0.896 |
ZS | 0.887 |
TBBK | 0.879 |
DMRC | 0.878 |
EA | 0.874 |
WDAY | 0.869 |
MDB | 0.866 |
TELA | 0.864 |
XENE | 0.864 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
AVDL | -0.893 |
CNFRZ | -0.865 |
IGLD | -0.85 |
PPTA | -0.849 |
MGEE | -0.845 |
AETH | -0.838 |
RING | -0.834 |
SLVO | -0.832 |
BNR | -0.83 |
GLDI | -0.828 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Athira Pharma, Inc. Koreliacija - Valiuta/Žaliavos
Athira Pharma, Inc. Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $-969 000 (0.00 %) |
EPS: | $-3.09 |
FY | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $-969 000 (0.00 %) |
EPS: | $-3.09 |
FY | 2022 |
Pajamos: | $0 |
Bruto pelnas: | $-1.05M (0.00 %) |
EPS: | $-2.31 |
FY | 2021 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-4.58 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Athira Pharma, Inc.
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.